CRISPR Therapeutics AG Reports Q1 2026 Financial Results
CRISPR Therapeutics (NASDAQ:CRSP) reported a reduced net loss of $122.9 million for the first quarter of 2026, down from $136.0 million in the same period last year. The company's cash reserves increased to $2.44 billion as of March 31, 2026, and its gene therapy product CASGEVY generated $43 million in revenue with over 500 patients treated globally.
Tickers: $CRSP